Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases

References

• Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967.
   PubMed Web of Science ®Google Scholar
• Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Extended report. Ann Rheum Dis. 2008;67(2):195–205.
   PubMed Web of Science ®Google Scholar
• Gamarra AI, Matteson EL, Rodriquez AI, et al. An historical review of systemic lupus erythematosus in Latin America. Med Sci Monit. 2004;10(7):RA171–RA185.
   Web of Science ®Google Scholar
• Bosnić D. [The history of systemic lupus erythematosus]. Reumatizam. 2009;56(2):9–15.
   Google Scholar
• Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–123.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124.
   PubMed Web of Science ®Google Scholar
• Miyagawa I, Nakano K, Nakayamada S, et al. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. Int J Rheum Dis. 2019;22(3):434–442.
   Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
   PubMed Web of Science ®Google Scholar
• Mallavarapu RK, Grimsley EW. The history of lupus erythematosus. South Med J. 2007;100(9):896–898.
   Web of Science ®Google Scholar
• Momose Y, Arai S, Eto H, et al. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus. J Dermatol. 2013;40(2):94–97.
   Web of Science ®Google Scholar
• Miyagawa I, Nakano K, Nakayamada S, et al. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. Int J Rheum Dis. 2020;23(4):549–558.
   Web of Science ®Google Scholar
• Kan H, Nagar S, Patel J, et al. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016;38(3):610–624.
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. 2019 European league against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400–1412.
   PubMed Web of Science ®Google Scholar
• Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615–1621.
   PubMed Web of Science ®Google Scholar
• Sawah SA, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2(1):66.
   Web of Science ®Google Scholar
• Goswami RP, Sit H, Ghosh P, et al. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre. Clin Rheumatol. 2019;38(4):1089–1097.
   PubMed Web of Science ®Google Scholar
• Fessler BJ, Alarcón GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–1480.
   Google Scholar
• Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40(6):831–841.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577–583.
   PubMed Web of Science ®Google Scholar
• Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–868.
   PubMedGoogle Scholar
• Medeiros Bezerra EL, Pereira Vilar MJ, Da Trindade Neto PB, et al. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3073–3078.
   Google Scholar
• Bykerk V, Sampalis J, Esdaile JM, et al. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150–154.
   Web of Science ®Google Scholar
• Ward NKZ, Linares-Koloffon C, Posligua A, et al. Cardiac manifestations of systemic lupus erythematous. Cardiol Rev. 2020 Sep 24. DOI:10.1097/CRD.0000000000000358. Online ahead of print.
   Google Scholar
• Muangchan C, Van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015;67(9):1237–1245.
   PubMed Web of Science ®Google Scholar
• Morel N, Bonjour M, Le Guern V, et al. Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Lupus. 2015;24(14):1479–1485.
   Web of Science ®Google Scholar
• Fernandez-Ruiz R, Bornkamp N, Kim MY, et al. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Res Ther. 2020;22(1):191.
   Web of Science ®Google Scholar
• Kishi C, Motegi S. i, Yasuda M, et al. Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients. J Dermatol. 2018;45(8):1020–1022.
   Web of Science ®Google Scholar
• Hosokawa Y, Oiwa H. Continuation rate, safety and efficacy of hydroxychloroquine treatment in a retrospective cohort of systemic lupus erythematosus in a Japanese municipal hospital. Intern Med. 2020;59:2485–2490.
   Web of Science ®Google Scholar
• Wakiya R, Kameda T, Nakashima S, et al. Efficacy and safety of hydroxychloroquine therapy for systemic lupus erythematosus patients depend on administration dose. Intern Med. 2020;59(17):2105–2112.
   Web of Science ®Google Scholar